News & Updates
Showing Respirology articles
Showing
Show Multimedia Only

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC
11 Jun 2026
byStephen Padilla
Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.








